Introduction
Brand name: Calfax K2‑7 (by Astemax Biotech)
Composition per capsule:
Calcitriol 0.25 mcg
Calcium carbonate IP 625 mg (equivalent to about 250 mg elemental calcium)
Vitamin K2‑7 (Menaquinone‑7) 45 mcg
Calfax K2‑7 is a calcium‑vitamin D‑vitamin K2 combination supplement designed to support bone mineralization, osteoporosis‑risk management, and skeletal health. Calcitriol (active vitamin D) enhances intestinal calcium absorption, calcium carbonate provides the main calcium source for bone‑matrix formation, and vitamin K2‑7 directs calcium into bone and away from vascular soft tissue, helping maintain bone density and vascular health.
Key uses
Prevention and adjunctive management of osteopenia and osteoporosis in adults, especially in elderly and post‑menopausal women.
Patients with low‑calcium‑intake diets, vitamin D deficiency, or those on long‑term steroids, anticonvulsants, or other drugs that impair bone metabolism.
Typical use and precautions
Usual dose is commonly 1 capsule once daily, preferably with food and at a fixed time, as per physician advice and product‑specific insert; strength‑wise regimen may differ slightly by market.
Avoid or use cautiously in hypercalcaemia, hypercalciuria, renal stones, severe renal impairment, or sarcoidosis and when on concomitant high‑dose vitamin D therapy; monitor serum calcium, phosphate, and renal function in prolonged use.
Astemax markets Calfax K2‑7 as a FSSAI‑approved, WHO‑GMP‑compliant supplement, suitable as a physician‑recommended bone‑health formulation in community and hospital practice.
